Published in FDA Law Weekly, February 18th, 2010
The new funding, expected to be approximately $1.59 million over 12 months, is in addition to option to license payments GT currently receives from KMOT. Work on the project is expected to begin immediately. As part of the agreement, KMOT is expected to purchase prototype devices and rely on GT for establishing the technical approach and regulatory strategy for potential entry of the new products into the U.S. and international markets.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly